EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities

Faith Hartley iD, Martin Ebert, Alistair M Cook iD

Clinical & Translational Immunology · 2025-01 · 14 (4)

DOI: 10.1002/cti2.70030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Translational Immunology, online erschienen am 08.04.2025. Verfasst von Faith Hartley und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical School University of Western Australia Perth WA Australia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most successful immunotherapies for solid malignancies to date, immune checkpoint inhibitors, target the essential role of T cells in antitumor immunity. However, T‐cell dysfunction presents a major hindrance to treatment efficacy, warranting research into combined treatment strategies for improving outcomes. The use of radiotherapy for this purpose has garnered much interest. Preclinical study has established that radiotherapy activates various immune mechanisms to improve T‐cell activation, localisation and function within tumors, which improves response to immune checkpoint inhibitors. However, so far, these strategies have not been successfully translated into the clinic. Here, we briefly reflect on the development of immune checkpoint inhibitors and the mechanistic insights revealed by an evolving understanding of T‐cell dysfunction in cancer, before providing an overview of the immunomodulatory effects of radiotherapy in the context of the T‐cell‐mediated antitumor immune response. We discuss the mixed results of clinical trials, comment on various factors that may preclude immuno‐radiotherapy responses in the clinic, and highlight priorities for preclinical and clinical study. Finally, we discuss the role of emerging combinations of radiotherapy and immunotherapy to potentially provide additional treatment options and improve outcomes for patients.

Schlagwörter

Stichwörter der Autor:innen

T cellsimmunotherapyradiotherapytranslational immunologytumor immunology

Autor:innen und Institutionen

  • Medical School University of Western Australia Perth WA Australia.
  • National Centre for Asbestos Related Diseases, Institute for Respiratory Health University of Western Australia Nedlands WA Australia.
  • School of Physics Mathematics and Computing University of Western Australia Perth WA Australia.
  • Department of Radiation Oncology Sir Charles Gairdner Hospital Nedlands WA Australia.
  • School of Biomedical Sciences University of Western Australia Nedlands WA Australia.

ORCID-Profile: Faith Hartley, Alistair M Cook

Zitieren

APA

Hartley, F., Ebert, M., & Cook, A. M. (2025). Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities. Clinical & Translational Immunology, 14(4). https://doi.org/10.1002/cti2.70030

Vancouver

Hartley F, Ebert M, Cook AM. Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities. Clinical & Translational Immunology. 2025;14(4). doi:10.1002/cti2.70030

BibTeX
@article{Hartley2025,
  author = {Hartley, Faith and Ebert, Martin and Cook, Alistair M},
  title = {Leveraging radiotherapy to improve immunotherapy outcomes: rationale, progress and research priorities},
  journal = {Clinical & Translational Immunology},
  year = {2025},
  volume = {14},
  number = {4},
  doi = {10.1002/cti2.70030}
}
Kostenlos starten →